Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/24/2021 11/25/2021 11/26/2021 11/29/2021 11/30/2021 Date
40(c) 38.4(c) 36.4(c) 36.1(c) 40.5 Last
12 236 37 934 117 718 18 073 51 568 Volume
-1.23% -4.00% -5.21% -0.82% +12.19% Change
More quotes
Estimated financial data (e)
Sales 2022 48,6 M 5,38 M 5,38 M
Net income 2022 -32,6 M -3,60 M -3,60 M
Net cash position 2022 252 M 27,9 M 27,9 M
P/E ratio 2022 -35,8x
Yield 2022 -
Sales 2023 146 M 16,2 M 16,2 M
Net income 2023 43,9 M 4,85 M 4,85 M
Net cash position 2023 297 M 32,9 M 32,9 M
P/E ratio 2023 30,1x
Yield 2023 -
Capitalization 1 151 M 127 M 127 M
EV / Sales 2022 18,5x
EV / Sales 2023 5,83x
Nbr of Employees 23
Free-Float 41,9%
More Financials
Company
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates... 
More about the company
Ratings of Biovica International AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOVICA INTERNATIONAL AB (PUBL)
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
11/19Biovica International
AQ
11/19Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
11/19Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
11/16Biovica International
AQ
11/16Biovica's DiviTum«TKa results published in Journal of Medical Economics
AQ
10/12BIOVICA INTERNATIONA : Biovica International
AQ
10/12BIOVICA INTERNATIONAL : Announcement from Biovica International's extra general meeting
AQ
09/23BIOVICA INTERNATIONAL : Notice of extra general meeting in Biovica International AB
AQ
09/20BIOVICA INTERNATIONAL AB(OM : BIOVIC B) added to S&P Global BMI Index
CI
09/15BIOVICA INTERNATIONAL : DiviTum«TKa results from SWOG study published in Clinical Cancer R..
AQ
09/15Biovica Announces DiviTum«TKa results from SWOG study published in Clinical Cancer Rese..
CI
09/14BIOVICA INTERNATIONAL : Promising DiviTumTKa results from BioItaLEE study presented at ESM..
AQ
09/13BIOVICA INTERNATIONA : Biovica International
AQ
More news
News in other languages on BIOVICA INTERNATIONAL AB (PUBL)

- No features available -

More news
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 36,10 SEK
Average target price 103,00 SEK
Spread / Average Target 185%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors